Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

While Tuesday’s results are from a mid-stage test, the stock market reaction indicates Wall Street sees it as a potential competitor to pneumococcal vaccines from Pfizer, Merck & Co. and GSK. Pfizer, ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $144.12, a high estimate of $155 ...

In the completed Phase 1/2a clinical trial (NCT03715985), assessing EVX-01 in combination with a PD-1 inhibitor, eight of twelve metastatic melanoma patients (67%) had objective clinical responses ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its 2024 Investor Day. While these events are often catalysts for stock, ...

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.